Skip to main content
News > News > Open Therapeutics and Bacmine SL Expand Partnership for Antibiotic Discovery

Open Therapeutics and Bacmine SL Expand Partnership for Antibiotic Discovery

Open Therapeutics and Bacmine SL Jointly form Subsidiary to Commercialize Novel Essential Protein Discovery Platform for Therapeutic Targets

CINCINNATI, Ohio, USA and MADRID, Spain – May 26, 2015 – Open Therapeutics, a biotechnology firm developing and commercializing enhanced bacteria (BactoBots) and viruses (ViruBots), and Bacmine SL, a synthetic biology company, formed Proteome Antibiotics, a joint-venture subsidiary.

Proteome Antibiotics is furthering the development and commercialization of a significant antibiotic discovery platform.  This unique platform provides novel therapeutic targets for pathogenic organisms, including antibiotic resistant pathogens.

According to a December 2014 report by the Wellcome Trust, David Cameron (Prime Minister, United Kingdom), and Chaired by the former chief economist of Goldman Sachs, Jim O’Neill, found that by 2050 without progress, ten million (10,000,000) people could die from antibiotic resistant pathogens.

In September 2014, USA President Barack Obama’s administration announced the emerging antibiotic resistance a threat to national security.  A policy agenda is now in place.

In December 2013, “The Lancet” an important infectious disease journal, reported that 58,000 infants in India died in 2012 as a result of antibiotic resistant pathogens.

On April 29th, 2015, the World Health Organization (WHO) announced critical findings in its “Worldwide country situation analysis:  Response to antimicrobial resistance” report.  In summary, the rapid emergence of antibiotic resistant pathogens may undermine the stability of governments and economies.

Through the identification of essential proteins, Proteome Antibiotics rapidly provides capable and responsible researchers, and the pharmaceutical industry, a significant range of new therapeutic targets to health-threatening organisms.

Jason E. Barkeloo, CEO of Open Therapeutics said, “This marks an exciting milestone in protecting human, animal, and plant health against pathogenic organisms.  We are enthusiastic about discovering, and helping capable and responsible researchers discover, new therapeutic targets against pathogenic health threats.  We believe this platform will enable scientists around the world to attack disease causing organisms such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant tuberculosis (MDR-TB).”

Dr. Pablo Pomposiello, CEO of Bacmine SL added: “Our platform combines the power of bacterial genetics with the specificity of antibodies.  This combination results in a uniquely fast and powerful discovery system that can go from protein extraction to potential antibiotic targets within six months. We achieved a significant proof-of-concept.  We are now ready to apply our experience to high impact pathogens. The antibiotic field is ripe for new ideas and applications, and synthetic biology provides a much needed solution to the growing problem of antibiotic resistant pathogens.”

Proteome Antibiotics uses an Open Therapeutics platform business model.  This new pharmaceutical business model enables capable and responsible researchers around the world in developing antibiotic targets for their populations.

View as a .PDF

About Bacmine SL

Bacmine is a synthetic biology company that designs bacterial cell factories for production of customized bioactive molecules and whole-cell catalysis. Bacmine has a successful track record in finding solutions for the manufacturing industry in metabolic engineering, design of novel biologicals, and generation and screening of large libraries of single-domain recombinant antibodies. Bacmine is developing tools for the next generation of Synthetic Biology, and is headquartered in Madrid, Spain. Visit us at for more information.


Pablo Pomposiello Miravent, PhD
+34 656 939 859

Bacmine SL
Calle Santiago Grisolía, 2
Tres Cantos 28760


About Open Therapeutics LLC

Open Therapeutics is a global biotechnology firm that rapidly prototypes synthetic biology products for expert industrial customers.  We create open, patented, and proprietary bacterial (BactoBots) and viral (ViruBots) technologies. These organism-based MicrobialBots perform functions for water, chemical, and pharmaceutical industries.  To achieve global scale, the Company developed a unique, “open” synthetic biology business model locked down with a genetic rights management (GeRM™) system.  The Company is headquartered in Cincinnati, Ohio with laboratory operations in Covington, Kentucky and Madrid, Spain via its strategic partner, Bacmine SL.

Open Therapeutics is a framework supporting a global ecosystem of responsible and capable research scientists working collaboratively on development projects to reduce cost, time, and risks of developing new therapeutics applications with commercial viability. Specifically, we focus on microbial biology to understand our vast new dimension therapeutic options. But because the field of microbial biology may cause unintended consequences, a healthy dialogue must be had for how to best progress with synthetic biology.

For more information on Open Therapeutics, visit its web site at


Jason E. Barkeloo
+1.513.252.2901 or @MicrobialBot

We Believe

Open Therapeutics crowdsources orphan and dormant therapeutic intellectual properties (IP) to scientists around the world. The goal is advancing research that ordinarily has not generated a public value or been recognized. This approach particularly helps underserved scientists to collaborate with their more financially capable colleagues.

How open science helps researchers succeed:

Open access, open data, open source, and other open scholarship practices are growing in popularity and necessity. However, widespread adoption of these practices has not yet been achieved. One reason is that researchers are uncertain about how sharing their work will affect their careers.

The review of the literature demonstrates that open science is associated with increases in citations, media attention, potential collaborators, job opportunities, and funding opportunities. These findings are evidence that open science practices bring significant benefits to researchers relative to more traditional closed practices.

Secured By miniOrange